Transient Receptor Potential Vanilloid 1 Activation Mediates the Anti-inflammatory Effects of the Tripeptide KPV in Intestinal Epithelial Cells
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D
Gastroenterology · Vol. 134(1) · pp. 129–141 · 2008
Mechanistic study establishing how KPV exerts its anti-inflammatory effects in intestinal epithelial cells via TRPV1 receptor activation and NF-κB inhibition. Demonstrates significant reduction in colitis severity in animal models and identifies the cellular pathway responsible for KPV's gut-protective effects.
Key Findings
KPV activates TRPV1 receptors on intestinal epithelial cells to suppress NF-κB
Significantly reduces colitis severity scores in DSS-induced colitis mouse model
Decreases pro-inflammatory cytokines (TNF-α, IL-1β, IL-8) in inflamed intestinal tissue
Oral delivery achieves effective concentrations in intestinal tissue
Anti-inflammatory effects are localized to gut without systemic immunosuppression
Methodology
In vitro intestinal epithelial cell studies combined with DSS-induced colitis mouse model. NF-κB reporter assays, cytokine ELISA, and histological scoring of colitis severity.
Limitations
Mouse colitis model may not fully replicate human IBD pathophysiology. Human clinical trials not yet completed.
Protocols Using This Research
Tags
Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.
Related Research
Build a protocol around this research
Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.
Start Assessment